YD Bio Ltd (YDESW) SEC Filings

YD Bio Ltd (YDES) director and CEO Dr. Ethan Shen reported purchasing 18,378 Ordinary Shares on September 4, 2026, in the open market at a weighted average price of $3.67 per share, with individual trade prices ranging from $3.50 to $3.70.

After this transaction, Dr. Shen holds 11,242,531 Ordinary Shares directly and 43,120,858 Ordinary Shares indirectly through YD Biopharma Holding Limited and related trust entities, of which he is the beneficial owner. No Rule 10b5-1 trading plan is reported.

YD Bio Limited reported the launch of two nutraceutical, chrono-nutrition formulations in Taiwan as part of a new physician-partnership initiative. The products, a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula, were co-developed with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute, a physician-led health education platform with 233,000 YouTube subscribers. The company frames this as the first deployment of a repeatable physician-partnership model intended to be capital-light, generate recurring consumer revenue, and build relationships with health-conscious consumers that may support future engagement with its regulated diagnostics and clinical services offerings.

YD Bio Ltd director Lu Shao-Ta reported equity compensation activity and updated share holdings. On June 30, 2026, he exercised 5,749 restricted share units (RSUs) into 5,749 ordinary shares at a stated price of $0.00 per share and received a new grant of 5,749 RSUs.

The RSUs relate to a March 31, 2026 award under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments based on a seven‑day volume‑weighted average price. Following these transactions, Lu holds 7,830 ordinary shares directly and 51,151 ordinary shares indirectly through his spouse.

YD Bio Ltd director Chang Kochi reported equity compensation activity involving Restricted Share Units (RSUs) and ordinary shares. On June 30, 2026, Kochi exercised 5,749 RSUs into the same number of ordinary shares at a stated price of $0.0000 per share, increasing direct holdings to 7,830 ordinary shares.

On the same date, Kochi also received a new grant of 5,749 RSUs with each RSU representing one ordinary share of YD Bio Ltd. According to the equity plan, the RSUs relate to a target aggregate grant date fair value of $60,000, vesting in four equal quarterly installments determined using a seven trading-day volume-weighted average price.

YD Bio Limited, a Cayman Islands company listed on the Nasdaq Global Market, files its annual report describing a young, loss-making healthcare business built around cancer blood tests and ophthalmology drugs. As of December 31, 2025, it had 70,789,261 ordinary shares and 15,142,911 warrants outstanding.

The report explains that YD Bio was created through a Business Combination with Breeze Holdings Acquisition Corp. and now owns all shares of YD Biopharma. Management discloses recurring losses, significant negative cash flow and substantial doubt about the company’s ability to continue as a going concern without new financing.

Key risks include dependence on critical IP licenses from EG BioMed and 3D Global, reliance on third‑party manufacturers, heavy revenue concentration in three major customers accounting for about 53.7% of 2025 revenue, and limited public‑company experience in the management team.

The company highlights extensive regulatory and reimbursement uncertainty: its cancer tests are Laboratory Developed Tests, future FDA oversight could change, and commercialization would require complex U.S. and foreign approvals and clinical trials. YD Bio is also exposed to Taiwan‑specific geopolitical and natural disaster risks, intellectual property disputes, potential PFIC and U.S. tax issues, and Nasdaq listing and dilution risks from public and private warrants.

YD Bio Ltd director Lu Shao-Ta updated his initial ownership report through an amended Form 3. The amendment adds disclosure of 51,151 Ordinary Shares held indirectly through his spouse that were previously omitted from his original Form 3 and one subsequent Form 4. This change reflects a correction in reported holdings, not a new share transaction.

YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.

YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.

The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.

YD Bio Ltd director Lu Shao-Ta has filed an initial Form 3 insider ownership report for YD Bio Ltd. The filing lists no reportable transactions or holdings, indicating this is an initial regulatory disclosure of insider status rather than a record of recent trading activity.